RESEARCH ARTICLE

A Comprehensive Spectroscopic and Computational Investigation to Probe the Interaction of Antineoplastic Drug Nordihydroguaiaretic Acid with Serum Albumins

Saima Nusrat1, Mohammad Khursheed Siddiqi1, Masihuz Zaman1, Nida Zaidi1, Mohammad Rehan Ajmal1, Parvez Alam1, Atiyatul Qadeer1, Ali Saber Abdelhameed2, Rizwan Hasan Khan1*

1 Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh – 202002, India, 2 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia

* rizwankhan@hotmail.com

Abstract

Exogenous drugs that are used as antidote against chemotherapy, inflammation or viral infection, gets absorbed and interacts reversibly to the major serum transport protein i.e. albumins, upon entering the circulatory system. To have a structural guideline in the rational drug designing and in the synthesis of drugs with greater efficacy, the binding mechanism of an antineoplastic and anti-inflammatory drug Nordihydroguaiaretic acid (NDGA) with human and bovine serum albumins (HSA & BSA) were examined by spectroscopic and computational methods. NDGA binds to site II of HSA with binding constant ($K_b$) ~10^5 M^{-1} and free energy ($\Delta G$) ~ -7.5 kcal.mol^{-1}. It also binds at site II of BSA but with lesser binding affinity ($K_b$) ~10^5 M^{-1} and $\Delta G$ ~ -6.5 kcal.mol^{-1}. The negative value of $\Delta G$, $\Delta H$ and $\Delta S$ for both the albumins at three different temperatures confirmed that the complex formation process between albumins and NDGA is spontaneous and exothermic. Furthermore, hydrogen bonds and hydrophobic interactions are the main forces involved in complex formation of NDGA with both the albumins as evaluated from fluorescence and molecular docking results. Binding of NDGA to both the albumins alter the conformation and causes minor change in the secondary structure of proteins as indicated by the CD spectra.

1. Introduction

The protein-drug interaction has been known as an extensive aspect towards the availability, efficacy and transport of drugs, for many years [1]. Drugs interact with circulating serum albumin of blood in a reversible manner and remarkably influence their absorption, apparent
distribution volume, metabolism and excretion performance [2,3]. In addition, solubility of hydrophobic drugs in plasma improves on interaction with serum albumin which regulate their distribution to cells both in-vivo and in-vitro and consequently affect their disposition and efficacy [4]. Drug interaction with albumin also minimizes the rate of clearance and raises the plasma half-life of the drug. The binding affinities of various drugs and natural products to serum albumin decide their distribution and metabolism [5]. Thus, to study protein-drug interaction is essential to have an insight of the transport and distribution of drugs, and for the interpretation of the mechanism behind their action and pharmaceutical dynamics [6].

The polyphenolic compounds are notably considered for antitumor activity against human malignant tumors, such as melanoma, glioblastoma and adenocarcinoma of prostate and lungs [7], and thus considered as drug. One such naturally occurring polyphenol, Nordihydroguaiaretic acid (NDGA), is the dominant metabolite of Creosote bush (Larrea tridentate) which is used as remedy in the treatment of diversified form of diseases that include cardiovascular disorders, neurological disorders and different types of cancer [8,9]. It has been considered since decades due to its advancement as antineoplastic, antiviral and anti-inflammatory characteristic attributes [8,10]. NDGA acquires a broad spectrum of biological properties and encompasses o-dihydroxy (catechol) group; bearing four hydroxyl groups of two phenols on the edges and hydrocarbon at the centre. Further, it is identified as a strong antioxidant and an in-vitro scavenger of reactive oxygen species (ROS), with distinct valuable health effects [11,12]. NDGA has also been acknowledged to have potent anti-amyloidogenic and fibril disaggregating properties [13,14,15]. Being a lipoygenase inhibitor NDGA has been shown to prevent the toxicity of Aβ on rat hippocampal neurons [14]. It also obstructs the tyrosine kinase behaviour of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells [16]. Thus, the study of NDGA interaction with serum albumins has biological relevance. In the present study, an attempt has been made to understand and evaluate the binding affinity and mechanism of NDGA interaction with human serum albumin (HSA) and bovine serum albumin (BSA).

HSA comprises of 585 amino acid residues and possess three homologous domains I-III [17]. Each domain comprises of two sub domains (A and B) [2,18]. The sub domain IIA possess Sudlow’s site I whereas Sudlow’s site II is located in sub domain IIIA [19,20]. HSA and BSA have 76% of sequence homology and homologous disulphide bond arrangements [21]; however number of tryptophan residues differ (two in BSA whereas single in HSA). BSA possess three homologous domains (I-III), same sub domains and similar binding site as that of HSA but possess 583 amino acid residues [22].

In the present study, binding energetics of NDGA and serum albumins (HSA and BSA) were evaluated by the steady state fluorescence spectroscopic technique. Determination of binding site was performed by displacement studies. The conformational alteration was observed by CD spectroscopy and the size of NDGA-albumin complex were determined by DLS measurements. Recognition of the amino acid residues involved in interaction of NDGA and albumins were done by molecular docking studies.

2. Materials and Methods

2.1. Materials

Essentially globulin and fatty acid free Human serum albumin (A1887), Bovine serum albumin (A7030), Nordihydroguaiaretic acid (N5023), Warfarin (A2250) and Phenylbutazone (P8386) were procured from Sigma Aldrich. Diazepam was obtained from Ranbaxy Laboratories Ltd. All other reagents were of analytical grade. Double distilled water free from any fluorescent contaminants was used.
2.2. Preparation of Solutions

All experiments were carried out in 20 mM sodium phosphate buffer (pH 7.4). The stock solution of proteins (10 mg/ml) were also prepared in 20 mM sodium phosphate buffer pH 7.4 and dialyzed in the same buffer. The concentration of proteins were determined spectrophotometrically using extinction coefficient $E^{1\%}_{280\text{ nm}} = 5.3 \text{ M}^{-1}\text{.cm}^{-1}$ and $6.5 \text{ M}^{-1}\text{.cm}^{-1}$ (for HSA and BSA, respectively) on Perkin Elmer Lambda 25 spectrophotometer. NDGA (2 mg/ml) was prepared in ethanol which was diluted in sodium phosphate buffer pH 7.4, for further use.

2.3. Steady State Fluorescence Quenching Measurements

Quenching may occur due to different molecular interactions viz. ground-state complex formation, collisional quenching, excited state reactions, molecular rearrangements and energy transfer. Quenching is classified as either dynamic or static quenching [23]. Dynamic quenching results from the collisional encounter between the fluorophore and the quencher whereas static quenching arises due to the ground state complex formation between the fluorophore and the quencher. Dynamic and static quenching can be differentiated by their dependence on temperature and viscosity. Fluorescence emission spectra were recorded on a Schimadzu 5301 PC fluorescence spectrophotometer equipped with a water circulator (JulaboEyela). The excitation and emission slit width were set at 3 nm and 5 nm. Fluorescence measurements of HSA & BSA (5 μM each) solutions were taken during separate titration with NDGA (0–50 μM) from 1:0 to 1:10 molar ratio of protein to drug (at an increments of 5 μM), in a dual-path length fluorescence cuvette (10 × 3.5 mm). The experiment was carried out at three different temperatures (298 K, 303 K and 310 K) in order to monitor the temperature dependence of serum albumin (HSA & BSA) and NDGA interaction. Excitation wavelength of 295 nm was selected to avoid possibility of fluorescence emission by tyrosine residues [24]. The emission spectra were recorded in the wavelength range of 300–450 nm. Respective blanks were subtracted from the spectra. The data obtained were analyzed according to linear Stern-Volmer equation [25]:

$$\frac{F_o}{F} = K_{sv}\left[Q\right] + 1 = k_q\tau_o + 1$$  \hspace{1cm} (1)

where, $F_o$ and $F$ are the fluorescence intensities in the absence and presence of NDGA (quencher), $K_{sv}$ is the Stern–Volmer quenching constant (measuring the efficiency of quenching), $k_q$ is the bimolecular rate constant of the quenching reaction and $\tau_o$ is the average integral fluorescence life time of tryptophan which is $\sim 10^{-9}$ s [26]. For the quenching process, the binding constant and the number of binding site were obtained by modified Stern-Volmer equation [26]:

$$\log\left(\frac{F_o}{F} - 1\right) = \log k_b + n\log[Q]$$  \hspace{1cm} (2)

where, $K_b$ is the binding constant, $n$ is the number of binding sites, $[Q]$ is the concentration of quencher i.e. NDGA. The change in free energy ($\Delta G^°$) was calculated from Gibbs-Helmholtz equation (Eq 3) whereas the change in enthalpy ($\Delta H^°$) and entropy ($\Delta S^°$) at different temperatures were analyzed from the Van’t Hoff equation (Eq 4):

$$\Delta G^° = -RT\ln K_b$$  \hspace{1cm} (3)

$$\ln K_b = \frac{-\Delta H}{R} + \frac{\Delta S}{R}$$  \hspace{1cm} (4)

where, $R$ (1.987 cal.mol$^{-1}$·K$^{-1}$) is gas constant and $T$ is the absolute temperature (K).
The synchronous fluorescence spectra were recorded when $\Delta \lambda$ (difference between the excitation and emission wavelength) is 60 nm (for tryptophan) and 15 nm (for tyrosine) for HSA and BSA (5 $\mu$M each) in the absence and presence of 1:10 molar ratio of protein to NDGA (0–50 $\mu$M) over a wavelength range of 280–400 nm.

2.4. UV-Visible Spectroscopic Measurements

Absorption measurements were performed at 37°C on Perkin-Elmer Lambda 25 double beam UV–vis spectrophotometer attached with a peltier temperature programmer-1 (PTP–1). A fixed concentration of HSA and BSA (10 $\mu$M each) was titrated with NDGA (0–100 $\mu$M) from 1:0 to 1:10 molar ratio of protein to drug and the respective blanks were subtracted.

2.5. Fluorescence Resonance Energy Transfer (FRET) Measurements

The fluorescence spectra of HSA & BSA (5 $\mu$M each) and absorption the spectra of NDGA (5 $\mu$M) in the wavelength range of 300–400 nm were scanned at 25°C as mentioned above. By Forster’s theory, the efficiency of energy transfer (E) is calculated using the following equation:

$$E = 1 - \frac{F}{F_0} = \frac{R_0^6}{R_0^6 + r^6}$$

where, $F_0$ and $F$ are the fluorescence intensities of HSA and BSA in the absence and presence of NDGA respectively, $r$ is the distance between the donor and the acceptor molecules and $R_0$ is the critical distance at which transfer efficiency is 50% which can be calculated from the following equation:

$$R_0^6 = 8.79 \times 10^{-25} K^2 n^{-4} \phi J$$

where, $K^2$ is the orientation factor related to the geometry of the donor and acceptor of dipoles, $n$ is the refractive index of the medium, $\phi$ is the fluorescence quantum yield of the donor in the absence of acceptor, and $J$ expresses the degree of spectral overlap between the donor emission and the acceptor absorption which can be evaluated by integrating the overlap spectral area in the wavelength range of 300–400 nm, from the following equation:

$$J = \int_{\lambda_1}^{\lambda_2} \frac{F(\lambda) \epsilon(\lambda) d\lambda}{\int_{\lambda_1}^{\lambda_2} F(\lambda) d\lambda}$$

where, $F(\lambda)$ is the fluorescence intensity of the donor at wavelength range $\lambda$ which is dimensionless, and $\epsilon(\lambda)$ is the molar absorptivity (extinction coefficient) of the acceptor at wavelength $\lambda$ in M$^{-1}\text{cm}^{-1}$. The values for $K^2$, $\phi$ and $n$ were taken as 2/3, 0.15 and 1.336, respectively (for HSA as well as for BSA) [28].

2.6. Circular Dichroic Measurements

The far-UV and near-UV CD spectra of HSA and BSA in the absence and presence of NDGA were obtained using JASCO-J815 spectropolarimeter equipped with a Peltier-type temperature controller. Calibration of the instrument was performed with d-10-camphorsulfonic acid. All the CD measurements were done at 25°C. Spectra were obtained with 50 nm/min scan speed, 0.1 nm data pitch and a response time of 2 s. Each spectrum obtained was the average of 2 scans [29]. The path length of the cells were 0.1 cm for far-UV CD (190–250 nm) and 1 cm for near-UV CD (250–300 nm) measurements. The HSA and BSA concentration for far and near-
UV CD measurements were taken as 5 μM and 10 μM. The percent of secondary structure was estimated by using online K_{2}D software.

2.7. Dynamic Light Scattering (DLS) Measurements

DLS measurements were performed at 830 nm on a DynaPro-TC-04 dynamic light scattering equipment (Protein Solutions, Wyatt Technology, Santa Barbara, CA) attached with a temperature-controlled micro sampler. HSA and BSA (2 mg/ml each) were incubated with NDGA (25 μM and 50 μM) in the protein to drug molar ratio of 1:0, 1:5 and 1:10 for 8 hours. Further, the samples were spun at 10,000 rpm for 10 min and then filtered through 0.22 μm and 0.02 μm Whatman syringe filters into a 12 μl quartz cuvette \[30\]. For each experiment, 20 measurements were taken. Mean hydrodynamic radius \(R_h\) and polydispersity were evaluated by using Dynamics 6.10.0.10 software at optimized resolution \[31\]. The \(R_h\) was measured on the basis of an autocorrelation analysis of scattered light intensity data depending on translation diffusion coefficient by Stoke's-Einstein relationship:

\[
R_h = \frac{kT}{6\pi\eta D} \tag{8}
\]

where, \(R_h\) is the hydrodynamic radius, \(k\) is Boltzmann constant, \(T\) is temperature, \(\eta\) is the viscosity of water and \(D\) is diffusion coefficient \[32\].

2.8. Molecular Docking

The crystal structure of HSA (PDB id: 1AO6) and of BSA (PDB id: 4F5S) were taken from Brookhaven Protein Data Bank and the 3D structure of NDGA (CID: 4534) was obtained from PubChem. The docking studies were performed by auto dock 4.2.0 software \[33\]. Lamarckian genetic algorithm (LGA) implemented with an adaptive local method search was applied to rule out the possible conformation of NDGA that binds to the protein. Hydrogen atoms and water molecules were eliminated and then, partial Kollman charges were designated to the proteins (HSA and BSA). The proteins were set to be rigid and all the torsional bonds were taken as being free during the docking process. The solvent molecules were not considered during docking. To reveal the binding site of NDGA on HSA and BSA, blind docking were performed and the grid size was set to be 126, 126 and 126 along the X, Y and Z axes with 0.564 Å grid spacing. Auto dock parameters were used with 150 as GA population size and 2,500,000 as maximum number of energy evolutions. The ten best solutions based on docking score were retained for further investigations. Discovery studio 3.5 was used to visualize and recognize the residues involved in the binding process.

2.9. Statistical Analysis

Results were shown as the means and the standard deviation (S.D.) values, with \(n = 3\) as the number of independent experiments.

3. Results and Discussion

3.1. NDGA Induced Fluorescence Quenching of HSA and BSA

Fluorescence intensity measurement is a sensitive tool to probe the protein conformation and structure when microenvironment around fluorophore (Tyr, Trp and Phe) gets altered \[34\]. The drug (NDGA) molecule quenches the fluorescence intensity of the albumins upto the ratio where it gets almost constant (from 1:0 to 1:10 molar ratio of protein to drug), due to its interaction with the fluorophores present in the proteins. Strikingly, intrinsic fluorescence property
of protein is attributed due to the presence of aromatic amino acid residues viz, Trp, Tyr and Phe [35,36]. As shown in (Fig 1A and 1B) NDGA molecule quenched the fluorescence intensity of Trp in both the proteins. The increase in the concentration of NDGA caused decrease in the fluorescence intensity of HSA and BSA. However, addition of NDGA to proteins beyond 1:10 molar ratio of protein to NDGA does not caused any further decrement in the fluorescence intensity. This decrease in fluorescence intensities was accompanied by a blue shift of 14 nm and 10 nm for HSA and BSA, respectively. The decrement in fluorescence intensity with blue shift signifies that the interaction of NDGA with proteins resulted in alteration in microenvironment around tryptophan residue and moved it to a more hydrophobic environment [37,38]. The binding parameters obtained from fluorescence measurements according to Stern-Volmer equation are summarized in Table 1 (Fig 2A and 2B). Diffusion coefficient increases with increment in temperature resulting in higher dynamic

![Fig 1. Emission spectra of albumins in the absence and presence of increasing concentration of NDGA, from 1:0 to 1:10 molar ratio of albumins to NDGA. (A) HSA (B) BSA.](doi:10.1371/journal.pone.0158833.g001)

| Protein | Temp (K) | n | $K_{SV}$ (M$^{-1}$) | $K_{q}$ (M$^{-1}$ s$^{-1}$) | $K_{m}$ (M$^{-1}$) | $\Delta H$ (kcal.mol$^{-1}$) | $\Delta G$ (kcal.mol$^{-1}$) | $\Delta S$ (cal.mol$^{-1}$.K$^{-1}$) |
|---------|----------|---|--------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| HSA     | 298      | 1.1±0.02 | $(5.03±0.06) \times 10^4$ | $(5.03±0.06) \times 10^{13}$ | $(3.14±0.10) \times 10^5$ | -7.46±0.04 | -8.31±0.04 |
|         | 303      | 1.1±0.01 | $(3.20±0.05) \times 10^4$ | $(3.20±0.05) \times 10^{13}$ | $(2.22±0.17) \times 10^5$ | -15.80±0.06 | -7.38±0.03 |
|         | 310      | 1.1±0.02 | $(2.30±0.07) \times 10^4$ | $(2.30±0.07) \times 10^{13}$ | $(1.12±0.12) \times 10^5$ | -7.13±0.06 | -8.65±0.17 |
| BSA     | 298      | 1.1±0.03 | $(3.50±0.02) \times 10^4$ | $(3.50±0.02) \times 10^{13}$ | $(1.00±0.08) \times 10^5$ | -6.79±0.05 | -10.34±0.2 |
|         | 303      | 1.0±0.04 | $(2.92±0.07) \times 10^4$ | $(2.92±0.07) \times 10^{13}$ | $(5.57±0.09) \times 10^4$ | -17.11±0.04 | -6.55±0.03 |
|         | 310      | 1.0±0.02 | $(2.05±0.07) \times 10^4$ | $(2.05±0.07) \times 10^{13}$ | $(3.22±0.12) \times 10^4$ | -6.37±0.03 | -10.75±0.1 |

Table 1. Binding and thermodynamic parameters of Albumin-NDGA at different temperatures obtained from fluorescence quenching experiments$^a$.

$^a$ R$^2$ for all values ranges from 0.98 to 0.99

doi:10.1371/journal.pone.0158833.g001
doi:10.1371/journal.pone.0158833.t001
quenching constant value. In contrast, poorly bound complexes gets destabilized at higher temperature and therefore lowers the static quenching constant value [26]. As can be seen from Table 1 that $K_{sv}$ value decreases with increasing temperature that reflects the static nature of quenching process rather than dynamic quenching [39]. The value of $k_q$ were found to be 1000 times greater than the maximum scatter collision quenching constant of various quenchers with biopolymer ($2.0 \times 10^{10}$ M$^{-1}$ s$^{-1}$) which also strongly implies that fluorescence quenching of serum albumins (HSA & BSA) by NDGA occurred through static quenching mechanism [40].

The $K_b$ values obtained from the y-axis intercept of modified Stern-Volmer plot (Fig 3A and 3B), decreases with increase in temperature which suggests that higher temperature leads to the formation of less stable complex formation. The value of $n$ is almost equal to unity demonstrating that there is one independent class of binding site for NDGA on both HSA as well as BSA.

### 3.2. Estimation of Thermodynamic Parameters

Evaluation of thermodynamic parameters is significant as it provides information regarding the binding forces involved during protein-drug interaction. The enthalpy change ($\Delta H$) is calculated from the slope of the van’t Hoff plot as shown in Fig 4 whereas the entropy change ($\Delta S$) is calculated from the intercept (Fig 4). The binding energetics obtained from van’t Hoff plot and Gibbs-Helmholtz equations are summarized in Table 1. The negative $\Delta G$ value indicates that NDGA interacts with albumins (HSA and BSA) in a spontaneous manner and the negative value of $\Delta H$ signifies the interaction process to be exothermic. According to the rules summarized by Ross and Subramanian [41], the negative value of $\Delta S$ and $\Delta H$ dictates that hydrogen bond plays a crucial role in Albumin-NDGA (HSA & BSA) complex formation. The role of hydrogen bond can be justified by the structure of NDGA which possess four hydroxyl groups
that may contribute to the interaction of NDGA with the aromatic amino acid residues present in HSA and BSA. Significantly higher value of $\Delta H$ rules out the possibility of ionic forces as these forces are characterized by a $\Delta H \approx 0$ [41].

### 3.3. Probing Binding Site using Site Markers

To get an insight into the binding site of NDGA on HSA and BSA, fluorescence displacement experiment was performed through a basic approach of competitive binding between NDGA and site specific markers viz. warfarin (WAR), phenylbutazone (PBZ) for site I and diazepam (DIA) for site II [42,43]. Albumins (HSA and BSA) and marker concentration were kept constant in the molar ratio of 1:1 and NDGA ($0-50 \mu M$) was used from 1:0 to 1:10 molar ratio of protein to drug. The drugs usually bind HSA and BSA at two major binding sites, Sudlow’s site I and site II, that are located in the specialized cavities in subdomains IIA and IIIA, respectively [44]. For the determination of the binding site of NDGA on HSA and BSA the values of $K_{sv}$ in the absence and presence of markers (WAR, PBZ and DIA) were calculated by the Stern-Volmer equation and listed in Table 2. The value of $K_{sv}$ in case of HSA as well as BSA decreased in the presence of site marker, DIA (Sudlow site II marker), PBZ and WAR (Sudlow site I markers) indicating the competition between the drug (NDGA) and the site markers for the same binding site. But the value of $K_{sv}$ was found to decrease by ten times in the presence of DIA while the decrease in $K_{sv}$ in the presence of PBZ and WAR was not much smaller but was significant thus the binding of NDGA to site I cannot be neglected (Table 2). This confirms Sudlow’s site II as the primary binding site and Sudlow’s site I as the secondary binding site of NDGA on HSA as well as on BSA [45,46].

### 3.4. Effect of NDGA on HSA & BSA Absorption Spectra

UV-visible spectra of albumins give bands in the wavelength range of 250–300 nm which is a cumulative absorption of three aromatic amino acid residues viz. tryptophan, tyrosine and...
phenylalanine. Fig 5A and 5B shows the absorption spectra of HSA and BSA in the absence and presence of 1:0, 1:2, 1:4, 1:6, 1:8 and 1:10 molar ratio of protein to NDGA. It is evident from the graph obtained that NDGA interaction with HSA and BSA results in increase in absorbance around 280 nm which indicates the complex formation between NDGA and albumins (HSA and BSA) and thus resulted into the increase in maximal absorption peak (hyperchromic shift) [47].

3.5. Conformational Investigation

Synchronous fluorescence spectroscopy provides information about the change in microenvironment around the fluorophore (Trp and Tyr) present in the protein upon binding with the drug [48]. When the $\Delta \lambda$ is 60 nm and 15 nm, synchronous fluorescence spectroscopy describes about the perturbation in microenvironment in the vicinity of Trp and Tyr residues, respectively. Fig 6A and 6C shows the synchronous fluorescence spectra of HSA when the $\Delta \lambda$ was 60 nm and 15 nm, in the absence and presence of increasing protein to drug molar ratio of NDGA (from 1:0 to 1:10). Also, Fig 6B and 6D shows the synchronous fluorescence spectra of BSA, when the $\Delta \lambda$ was 60 nm and 15 nm, in the absence and presence of increasing protein to drug molar ratio of NDGA (from 1:0 to 1:10). A decrease in fluorescence intensity with no shift in $\lambda_{\text{max}}$ was observed when $\Delta \lambda = 60$ nm, indicating no change in the microenvironment around Trp, for HSA as well as for BSA, as shown in Fig 6A and 6B. In contrast, when $\Delta \lambda = 15$ nm, a

![Graph](image)

**Fig 4. Van’t Hoff plot for temperature dependence of $K_b$.** Obtained from fluorescence quenching of albumins by NDGA at 298 K, 303 K and 310 K. Results are mean of three independent experiments ($n = 3$) and the error bars show the standard deviation.

doi:10.1371/journal.pone.0158833.g004

doi:10.1371/journal.pone.0158833.t002

| Protein | $K_{sv}$ without site marker | $R^2$ | $K_{sv}$ with PBZ | $R^2$ | $K_{sv}$ with WAR | $R^2$ | $K_{sv}$ with Dia | $R^2$ |
|---------|-----------------------------|-------|-------------------|-------|-------------------|-------|-------------------|-------|
| HSA     | $5.03 \times 10^4$          | 0.99  | $1.20 \times 10^4$| 0.99  | $1.7 \times 10^4$ | 0.99  | $6.3 \times 10^3$ | 0.99  |
| BSA     | $3.50 \times 10^4$          | 0.99  | $1.02 \times 10^4$| 0.99  | $1.8 \times 10^4$ | 0.99  | $6.4 \times 10^3$ | 0.99  |

Table 2. Effect of site markers upon NDGA binding to HSA and BSA.
3.6. Steady State Fluorescence Resonance Energy Transfer (FRET)

FRET technique is widely used to determine the proximity of drug and spatial distance between a donor and an acceptor during protein-drug interaction. Fig 1 shows that on gradual titration of NDGA, the fluorescence intensity of tryptophan in HSA and BSA decreases. This indicates the transfer of energy from tryptophan to NDGA that results in quenching. The absorption spectrum of NDGA extensively overlaps the emission spectrum of both HSA and BSA as shown in Fig 7A and 7B. If the emission spectrum of donor (HSA and BSA) significantly overlaps with the absorption spectrum of acceptor (NDGA), these donor-acceptor pairs will be considered in Förster distance and the possibility of energy transfer could be ascertained [49]. Therefore, the degree of energy transfer depends upon the area of overlap and the distance between these donor-acceptor molecules (Fig 7A and 7B). Table 3 summarizes the parameters obtained by using the Eqs 5–7. The binding distance (r) obtained for the NDGA-Albumins (HSA & BSA) interactions are 1.43 nm & 1.51 nm, respectively. Further, the R0 value is 1.89 nm for both the systems. The value of r and R0 is in accordance with the Förster’s non-radiative energy transfer theory [48,50], which states that 0.5R0 < r < 1.5R0. This further justified that energy transfer has taken place from HSA and BSA to NDGA that resulted in the quenching of fluorescence intensity.

3.7. Circular Dichroism (CD) Analysis

CD spectroscopy plays an important role in the study of protein-drug interaction as it allows the characterization of secondary as well tertiary structure of the protein upon binding with the drug. Far-UV CD spectra is used to characterize the secondary structure [51] whereas near-UV
CD spectra is employed to observe modification in the tertiary structure of protein. **Fig 8A and 8B** represents the far-UV CD spectra of HSA and BSA at 1:0, 1:5 and 1:10 protein to NDGA molar ratio. In the absence of NDGA, HSA and BSA exhibits two characteristic peak which are around at 222 nm (n→π* transition) and 208 nm (π→π* transition), a characteristic of α-helix [52,53]. The spectra in the **Fig 8A and 8B** depicts that NDGA interaction with HSA (& BSA) led to a change in secondary structure of albumin resulting into the increment in helical content of protein. Using K2D software, the helicity of proteins were calculated. At 1:10 protein to drug molar ratio of NDGA the helicity was found to increase from 55.25±1.05% to 58.35

**Fig 6.** Synchronous fluorescence spectrum of HSA-NDGA (A) and BSA-NDGA (B) at Δλ = 60 nm and HSA-NDGA (C) and BSA-NDGA (D) at Δλ = 15 nm. doi:10.1371/journal.pone.0158833.g006
±1.75% in for HSA and from 62.71±1.37% to 65.60±1.28% for BSA. This indicates that NDGA stabilized the secondary structure of HSA and BSA. Fig 8C and 8D shows the near-UV CD spectra of HSA and BSA at 1:0, 1:5 and 1:10 molar ratio of protein to NDGA. Near-UV CD spectra of proteins in the absence of NDGA represents two minima at 262 nm and 268 nm and shoulders at 279 nm and 290 nm, respectively which are attributed to the disulfide bonds and aromatic chromophores [54]. In the presence of NDGA, the near-UV CD spectra of both the proteins showed some changes which signifies tertiary structure alterations.

3.8. Dynamic Light Scattering (DLS) Measurements

DLS is used to monitor the change in size of protein molecules [55,56]. Changes in size were monitored by measuring the hydrodynamic radii ($R_h$) of the complex formed i.e., NDGA-HSA & NDGA-BSA. Fig 9A, 9B and 9C represents the change in $R_h$ values of HSA upon interaction with 1:0, 1:5 and 1:10 molar ratio of protein to NDGA, Fig 9D, 9E and 9F shows the change in $R_h$ values of BSA upon interaction with 1:0, 1:5 and 1:10 molar ratio of protein to NDGA and the obtained DLS parameters i.e. $R_h$ and polydispersity are summarized in Table 4 [57]. $R_h$ of native HSA and BSA were found to be 3.6 nm & 3.8 nm, respectively which decreased upon interaction with NDGA. Plausibly, it may be due to the interaction of NDGA with albumins in such a manner that the solvent shell surrounding the protein got disrupted causing protein molecule to collapse leading to a decrease in hydrodynamic radii.

| Protein | J (cm$^3$.M$^{-1}$) | $R_h$ (nm) | r (nm) | $E_{FRET}$ |
|---------|------------------|-----------|-------|-----------|
| HSA     | 2.11 x 10$^{13}$ | 1.89      | 1.43  | 0.71      |
| BSA     | 2.11 x 10$^{13}$ | 1.89      | 1.51  | 0.62      |

doi:10.1371/journal.pone.0158833.g007

doi:10.1371/journal.pone.0158833.t003
3.9. Molecular Docking Studies on NDGA-Albumins (HSA & BSA) Interaction

The molecular docking studies were carried out to disclose the binding sites and amino acid residues involved in the interaction of NDGA to the different sites on HSA and BSA. Molecular docking results showed that NDGA primarily interacts with site II but also binds to site I on HSA as well as on BSA [46]. The best energy ranked results and the amino acid residues involved in the interaction are shown in Figs 10 and 11 and summarized in Table 5. As shown in (Fig 10A and 10C) and (Fig 10B and 10D), NDGA positively fits into the hydrophobic
compartment close to sub domain IIIA in Sudlow site II of HSA and BSA, with $\Delta G$ values of -7.65 kcal.mol$^{-1}$ and -7.12 kcal.mol$^{-1}$, respectively. NDGA interacts hydrophobically with Lys190, Ala191, Ala194, Lys195, Lys432, Lys436, Pro447, Asp451, Val455 and Val456 residues of HSA near site II whereas Asn429, Cys448, Asp451, Tyr452 and Gln459 forms hydrogen bonds with NDGA, as indicated by green dotted lines in Fig 10A. On the contrary Trp213, Arg217, Gln220, Lys294, Tyr340, Ala341, Ser343, Pro446, Asp450 and Leu454 residues present in site II of BSA interacts with NDGA hydrophobically and Arg194, Leu197, Arg198, Pro338, Glu339 and Val342 residues are involved in hydrogen bond formation (Fig 10B), at site II of BSA. Moreover, NDGA also interacts with crucial amino acid residues at site I of HSA and BSA, with $\Delta G$ values of -6.26 kcal.mol$^{-1}$ and -6.97 kcal.mol$^{-1}$, respectively as shown in (Fig 11A and 11B). The hydrogen bond is formed by Leu198, Ser202, Tyr452 and Val455 residues of Sudlow’s site I in HSA and Thr190, Ser191, Arg198 and Tyr451 residues of Sudlow’s site I in

Table 4. Hydrodynamic radii and polydispersity of HSA and BSA in the absence and presence of NDGA.

| Conditions   | $R_h$   | Pd%  |
|--------------|---------|------|
| A. HSA       | 3.6 ± 0.12 | 11.0 |
| B. HSA:NDGA (1:5) | 3.0 ± 0.14 | 11.9 |
| C. HSA:NDGA (1:10) | 2.7 ± 0.13 | 12.5 |
| D. BSA       | 3.8 ± 0.10 | 10.4 |
| E. BSA:NDGA (1:5) | 3.4 ± 0.11 | 11.5 |
| F. BSA:NDGA (1:10) | 2.8 ± 0.13 | 11.9 |

doi:10.1371/journal.pone.0158833.t004
4. Conclusion

In the present work we have performed the spectroscopic and molecular docking studies of an antineoplastic and anti-inflammatory drug NDGA with the water soluble model protein i.e. Human and Bovine serum albumins. Results illustrate that the mechanism of fluorescence quenching of HSA and BSA by NDGA is in a static manner and their binding process is spontaneous and enthalpically driven involving both hydrogen bonding and hydrophobic interactions. Synchronous fluorescence spectra show microenvironment change around the tryptophan and also the tyrosine residues. DLS results revealed that NDGA led to the BSA and -OH group of NDGA molecule. Thus, hydrogen bonding and hydrophobic interactions are the major binding forces involved in NDGA and albumin interaction [40].
Fig 11. Molecular docking of NDGA and albumins. (A) amino acid residues involved for NDGA interaction at site I of HSA (A) and BSA (B). (C) and (D) Cartoon model representing NDGA as stick while HSA and BSA are represented by ribbon model.

doi:10.1371/journal.pone.0158833.g011

Table 5. Molecular docking parameters obtained from Albumin- NDGA interaction.

| Binding Site | Amino acid residues                                                                 | Forces involved               | ΔG(kcal.mol⁻¹) |
|--------------|-------------------------------------------------------------------------------------|-------------------------------|----------------|
| HSA Site I   | Lys199,Trp214,Cys437, Pro447,Ala449,Asp451, Leu198,Ser202,Tyr452, Val455,           | Hydrophobic interaction       | -6.26          |
|              | Lys190,Ala191,Ala194, Lys195,Lys432,Lys436, Pro447,Asp451,Val455, Val456           | Hydrogen bond                 | -7.65          |
|              | Asn429,Cys448,Asp451, Tyr452,Gln459                                                 |                               |                |
| Site II      | Tyr149,Glu152,Tyr156, Lys187,Arg194,Ala290, Arg435                                  | Hydrophobic interaction       | -6.97          |
|              | Thr190,Ser191,Arg198, Tyr451                                                        | Hydrogen bond                 |                |
| BSA Site I   | Trp213,Arg217,Gln220, Lys294,Tyr340,Ala341, Ser343,Pro446,Asp450, Leu454            | Hydrophobic interaction       | -7.12          |
| Site II      | Arg194,Leu197,Arg198, Pro338,Glu339,Val342                                         | Hydrogen bond                 |                |

doi:10.1371/journal.pone.0158833.t005
decrement in hydrodynamic radii of albumins causing change in topology of proteins. Far-UV CD spectra indicated the increase in percent alpha helix when complexed with NDGA in case of HSA as well as BSA. Further, molecular docking and fluorescence displacement results indicated that the NDGA molecule actively binds to Sudlow’s site II of albumins (HSA and BSA) and also binds to Sudlow’s site I of both the albumins. Moreover, the values of ΔG calculated from molecular docking are concurrent with those obtained from fluorescence quenching experiment.

Being an effective ROS scavenger, NDGA has been proved to have encouraging relevance in the medication of diseases, like neurological disorders, cardiovascular diseases and cancers, and in the field of tissue engineering. Its medicinal properties have been supported by in vitro and in vivo experimental studies. In view of the developing appeal for anti-inflammatory and antineoplastic drugs their interaction with major carrier proteins like serum albumins, when used as a treatment drug could be momentous. As the binding of drug with carrier proteins is influential for the transport and metabolism of drug.

Acknowledgments

Facilities provided by Interdisciplinary Biotechnology Unit, AMU, Aligarh are highly acknowledged. SN and MZ are highly thankful to University Grant Commission, New Delhi, for financial assistance in the form of MANF-SRF. MKS is highly thankful to Department of Biotechnology (DBT) for financial assistance in the form of DBT-JRF (NET) fellowship. NZ is highly thankful to University Grant Commission, New Delhi, for financial assistance in the form of UGC-post doctoral fellowship. MRA is highly thankful to University Grant Commission, New Delhi, for financial assistance in the form of UGC-SRF (NET) fellowship. We are thankful to Dr. AtiyatulQadeer for the careful revision of the manuscript to fix the grammatical errors and improve the overall readability of the text. RHK is thankful to DBT and DST for project numbers BT/PR 13194/10/742/2009 and SR/SO/BB-0018/2011, respectively. The authors would like to extend their sincere appreciation to the Deanship of ScientificResearch at King Saud University for its funding this Research Group No. RG-1435-02

Author Contributions

Conceived and designed the experiments: SN RHK. Performed the experiments: SN MKS MZ MRA. Analyzed the data: SN NZ PA RHK. Contributed reagents/materials/analysis tools: MZ NZ PA RHK. Wrote the paper: SN MKS AQ NZ AS RHK.

References

1. Singh SS (2006) Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Current drug metabolism 7: 165–182. PMID: 16472108
2. Carter DC, Chang B, Ho JX, Keeling K, Krishnasami Z (1994) Preliminary crystallographic studies of four crystal forms of serum albumin. European Journal of Biochemistry 226: 1049–1052. PMID: 7813459
3. Perry JL, Il’ichev YV, Kempf VR, McClendon J, Park G, Manderville RA, et al. (2003) Binding of ochratoxin A derivatives to human serum albumin. The Journal of Physical Chemistry B 107: 6644–6647.
4. Olson RE, Christ DD (1996). Plasma Protein Binding of Drugs. Annual reports in medicinal chemistry 31: 327–336.
5. Zsila F, Bikadi Z, Simonyi M (2003) Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochemical pharmacology 65: 447–456. PMID: 12527398
6. Gong A, Zhu X, Hu Y, Yu S (2007) A fluorescence spectroscopic study of the interaction between epristeride and bovin serum albumine and its analytical application. Talanta 73: 668–673. doi: 10.1016/j.talanta.2007.04.041 PMID: 19073087
7. Liu L, Hudgins WR, Shack S, Yin MQ, Samid D (1995) Cinnamic acid: a natural product with potential use in cancer intervention. International journal of cancer 62: 345–350. PMID: 7628877
8. Lu J-M, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, et al. (2010) Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Medical science monitor: international medical journal of experimental and clinical research 16: RA93.
9. Arteaga S, Andrade-Cetto A, Cardenas R (2005) Larreatridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. Journal of ethnopharmacology 98: 231–239. PMID: 15814253
10. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, et al. (2005) Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast cancer research and treatment 94: 37–46. PMID: 16142439
11. Floriano-Sanchez E, Villanueva C, Noel Medina-Campos O, Rocha D (2006) Nordihydroguaiaretic acid is a potent in vitro scavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and prevents in vivo ozone-induced tyrosine nitration in lungs. Free radical research 40: 523–533. PMID: 16551579
12. You KM, Jong H-G, Kim HP (1999) Inhibition of cyclooxygenase/lipoxygenase from human platelets by polyhydroxylated/methoxylated flavonoids isolated from medicinal plants. Archives of pharmacal research 22: 18–24. PMID: 10071954
13. Matsuzaki K, Noguch T, Wakabayashi M, Ikeda K, Okada T, Ohashi Y, et al. (2007) Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes. BiochimicaetBiophysicaActa (BBA)-Biomembranes 1768: 122–130.
14. Goodman Y, Steiner MR, Steiner SM, Mattson MP (1994) Nordihydroguaiaretic acid protects hippocampal neurons against amyloid b-peptide toxicity, and attenuates free radical and calcium accumulation. Brain research 654: 171–176. PMID: 7982093
15. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H (2002) Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer’s β-amyloid fibrils in vitro. Journal of neurochemistry 81: 434–440. PMID: 12065652
16. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, et al. (2008) Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. Journal of cellular biochemistry 103: 624–635. PMID: 17562544
17. He XM, Carter DC (1992) Atomic structure and chemistry of human serum albumin.
18. Lakowicz JR (1999) Principles of fluorescence spectroscopy: Springer Science & Business Media.
19. Takikawa H, Sugiyama Y, Hanano M, Kurita M, Yoshida H, Sugimoto T (1987) A novel binding site for bile acids on human serum albumin. BiochimicaetBiophysicaActa (BBA)-General Subjects 926: 145–153.
20. Peters T (1985) Serum albumin. Advances in protein chemistry 37: 161–245. PMID: 3904348
21. Khan AB, Khan JM, Ali MS, Khan RH, Din K-u (2011) Spectroscopic approach of the interaction study of amphiphilic drugs with the serum albumins. Colloids and Surfaces B: Biointerfaces 87: 447–453. doi: 10.1016/j.colsurfb.2011.06.007 PMID: 21726987
22. Kragh-Hansen U (1981) Molecular aspects of ligand binding to serum albumin. Pharmacological Reviews 33: 17–53. PMID: 7027277
23. Qadeer A, Ahmad E, Zaman M, Khan MW, Khan JM, Rabbani G, et al. (2013) Concentration-dependent antagonistic persuasion of SDS and naphthalene derivatives on the fibrillation of stem bromelain. Archives of biochemistry and biophysics 540: 101–116. doi: 10.1016/j.abb.2013.10.015 PMID: 24184422
24. Vanderkooi JM, Calhoun DB, Englander SW (1987) On the prevalence of room-temperature protein phosphorescence. Science 236: 568–569. PMID: 3576185
25. Lakowicz JR (1999) Fluorophores. Principles of fluorescence spectroscopy: Springer. pp. 63–93.
26. Lakowicz JR (1999) Introduction to fluorescence. Principles of fluorescence spectroscopy: Springer. pp. 1–23.
27. Yuri V. Ifichev JLP, Simon JD (2002) Interaction of Ochratoxin A with Human Serum Albumin. Preferential Binding of the Dianion and pH Effects. Ann Phys 106: 452–459.
28. Kasai S, Horie T, Mizuma T, Awazu S (1987) Fluorescence energy transfer study of the relationship between the lone tryptophan residue and drug binding sites in human serum albumin. J Pharm Sci 76: 387–392. PMID: 3656100
29. Zaman M, Chaturvedi SK, Zaidi N, Qadeer A, Chandel TI, Nusrat S, et al. (2016) DNA induced aggregation of stem bromelain; a mechanistic insight. RSC Advances 6: 37591–37599.
30. Ahmad E, Sen P, Khan RH (2011) Structural stability as a probe for molecular evolution of homologous albumins studied by spectroscopy and bioinformatics. Cell Biochem Biophys 61: 313–325.

31. Jiang N, Yang C, Dong X, Sun X, Zhang D, Liu C (2014) An ESIPT fluorescent probe sensitive to protein α-helix structures. Organic &biomolecular chemistry 12: 5250–5259.

32. Paul BK, Samanta A, Guichhait N (2010) Exploring hydrophobic subdomain IIA of the protein bovine serum albumin in the native, intermediate, unfolded, and refolded states by a small fluorescence molecular reporter. The Journal of Physical Chemistry B 114: 6183–6196. doi: 10.1021jp1000041 PMID: 20397640

33. Alam P, Chaturvedi SK, Anwar T, Siddiqi MK, Ajmal MR, Badr G, et al. (2015) Biophysical and molecular docking insight into the interaction of cytosine b-D Arabinofuranoside with Human serum albumin. Journal of Luminescence. PMID: 26594061

34. Zaidi N, Nusrat S, Zaidi FK, Khan RH (2014) pH-dependent differential interacting mechanisms of sodium dodecyl sulfate with bovine serum albumin: a biophysical insight. The Journal of Physical Chemistry B 118: 13025–13036. doi: 10.1021/jp501515g PMID: 25338219

35. Sulikowska A (2002) Interaction of drugs with bovine and human serum albumin. Journal of molecular structure 614: 227–232.

36. Feroz SR, Mohamad SB, Bakri ZSD, Malek SNA, Tayyab S (2013) Probing the interaction of a therapeutic flavonoid, pinostrobin with human serum albumin: multiple spectroscopic and molecular modeling investigations. PloS one 8: e76067. doi: 10.1371/journal.pone.0076067 PMID: 24116089

37. Gentili PL, Ortica F, Favaro G (2008) Static and dynamic interaction of a naturally occurring photochromic molecule with bovine serum albumin studied by UV-visible absorption and fluorescence spectroscopy. The Journal of Physical Chemistry B 112: 16793–16801. doi: 10.1021/jp080922g PMID: 19367911

38. Zaidi N, Ajmal MR, Rabbani G, Ahmad E, Khan RH (2013) A comprehensive insight into binding of hipuric acid to human serum albumin: a study to uncover its impaired elimination through hemodialysis. PloS one 8: e71422. doi: 10.1371/journal.pone.0071422 PMID: 23951159

39. Ross PD, Subramanian S (1981) Thermodynamics of protein association reactions: forces contributing to stability. Biochemistry 20: 3096–3102. PMID: 7248271

40. Pettitas I, Bhattacharya AA, Twine S, East M, Curry S (2001) Crystal structure analysis of warfarin binding to human serum albumin anatomy of drug site I. Journal of Biological Chemistry 276: 22804–22809. PMID: 11285262

41. Ghuman J, Zunszain PA, Pettitas I, Bhattacharya AA, Otagiri M, Curry S (2005) Structural basis of the drug-binding specificity of human serum albumin. Journal of molecular biology 353: 38–52. PMID: 16169013

42. Sudlow G, Birkett DJ, Wade DN (1976) Further characterization of specific drug binding sites on human serum albumin. Molecular pharmacology 12: 1052–1061. PMID: 1004490

43. Chi Z, Liu R (2010) Phenotypic characterization of the binding of tetracycline to human serum albumin. Biomacromolecules 12: 203–209. doi: 10.1021/bm1011568 PMID: 21142141

44. Zaidi N, Ahmad E, Rehan M, Rabbani G, Ajmal MR, Zaidi Y, et al. (2013) Biophysical insight into furosemide binding to human serum albumin: a study to unveil its impaired binding in uremia. The Journal of Physical Chemistry B 117: 2595–2604. doi: 10.1021/jp3069877 PMID: 23438181

45. Chaturvedi SK, Ahmad E, Khan JM, Alam P, Ishikhar M, Khan RH (2015) Elucidating the interaction of limonene with bovine serum albumin: a multi-technique approach. Molecular BioSystems 11: 307–316. doi: 10.1039/c4mb00548a PMID: 25382435

46. Varlan A, Hillebrand M (2010) Bovine and human serum albumin interactions with 3-carboxyphenoxathiin studied by fluorescence and circular dichroism spectroscopy. Molecules 15: 3905–3919. doi: 10.3390/molecules15063905 PMID: 20657416

47. Förster T (1948) Intermolecular energy migration and fluorescence. Ann Phys 2 473: 55–75.

48. Hu Y-J, Liu Y, Zhang L-X, Zhao R-M, Qu S-S (2005) Studies of interaction between colchicine and bovine serum albumin by fluorescence quenching method. Journal of Molecular Structure 750: 174–178.

49. Qadeer A, Zaman M, Khan RH (2014) Inhibitory effect of post-micellar SDS concentration on thermal aggregation and activity of papain. Biochemistry (Moscow) 79: 785–796.

50. Zhang H-M, Chen T-T, Zhou Q-H, Wang Y-Q (2009) Binding of caffeine, theophylline, and theobromine with human serum albumin: A spectroscopic study. Journal of molecular structure 938: 221–228.

51. Shu Y, Liu M, Chen S, Chen X, Wang J (2011) New insight into molecular interactions of imidazolium ionic liquids with bovine serum albumin. The Journal of Physical Chemistry B 115: 12306–12314. doi: 10.1021/jp2071925 PMID: 21919506
52. Ahmad B, Parveen S, Khan RH (2006) Effect of albumin conformation on the binding of ciprofloxacin to human serum albumin: a novel approach directly assigning binding site. Biomacromolecules 7: 1350–1356. PMID: 16602760

53. Zaman M, Ahmad E, Qadeer A, Rabbani G, Khan RH (2014) Nanoparticles in relation to peptide and protein aggregation. International journal of nanomedicine 9: 899. doi: 10.2147/IJN.S54171 PMID: 24611007

54. Ajmal MR, Nusrat S, Alam P, Zaidi N, Badr G, Mahmoud MH, et al. (2016) Differential mode of interaction of ThioflavinT with native b structural motif in human a 1-acid glycoprotein and cross beta sheet of its amyloid: Biophysical and molecular docking approach. Journal of molecular structure 1117: 208–217.

55. Yu M, Ding Z, Jiang F, Ding X, Sun J, Chen S, et al. (2011) Analysis of binding interaction between pegylatedpuerarin and bovine serum albumin by spectroscopic methods and dynamic light scattering. Spectrochimica Acta Part A MolBiomolSpectrosc 83: 453–460.

56. Ajmal MR, Zaidi N, Alam P, Nusrat S, Siddiqi MK, Badr G, et al. (2015) Insight into the Interaction of antitubercular and anticancer compound Clofazimine with Human Serum Albumin: spectroscopy and molecular modelling. Journal of Biomolecular Structure and Dynamics: 1–42.

57. Ajmal MR, Abdelhameed AS, Alam P, Khan RH (2016) Interaction of new kinase inhibitors cabozantinib and tofacitinib with human serum alpha-1 acid glycoprotein. A comprehensive spectroscopic and molecular Docking approach.Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 159: 199–208.